Research programme: protein degradation therapeutics - Boehringer Ingelheim/VantAI
Latest Information Update: 22 Apr 2022
At a glance
- Originator Boehringer Ingelheim; VantAI
- Class Small molecules
- Mechanism of Action Proteolysis; Ubiquitin protein ligase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 20 Apr 2022 VantAI and Boehringer Ingelheim agree to co-develop protein degrader therapeutics for Unspecified indication
- 20 Apr 2022 Early research in Unspecified in Germany (unspecified route), prior to April 2022
- 20 Apr 2022 Early research in Unspecified in USA (unspecified route), prior to April 2022